EA202192254A1 - Fcmr-связывающие молекулы и их применение - Google Patents

Fcmr-связывающие молекулы и их применение

Info

Publication number
EA202192254A1
EA202192254A1 EA202192254A EA202192254A EA202192254A1 EA 202192254 A1 EA202192254 A1 EA 202192254A1 EA 202192254 A EA202192254 A EA 202192254A EA 202192254 A EA202192254 A EA 202192254A EA 202192254 A1 EA202192254 A1 EA 202192254A1
Authority
EA
Eurasian Patent Office
Prior art keywords
fcmr
application
binding molecules
antibodies
pharmaceutical compositions
Prior art date
Application number
EA202192254A
Other languages
English (en)
Inventor
Ричард Брокс
Жаклин М. Мэйсон
Марк Р. Брэй
Original Assignee
Юниверсити Хелт Нетворк
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Юниверсити Хелт Нетворк filed Critical Юниверсити Хелт Нетворк
Publication of EA202192254A1 publication Critical patent/EA202192254A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

В настоящем изобретении предложены новые антитела к FCMR, фармацевтические композиции, содержащие такие антитела, и терапевтические способы применения таких антител и фармацевтических композиций для лечения заболеваний, таких как рак или аутоиммунное заболевание.
EA202192254A 2019-02-15 2020-02-14 Fcmr-связывающие молекулы и их применение EA202192254A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962806237P 2019-02-15 2019-02-15
PCT/CA2020/050195 WO2020163962A1 (en) 2019-02-15 2020-02-14 Fcmr-binding molecules and uses thereof

Publications (1)

Publication Number Publication Date
EA202192254A1 true EA202192254A1 (ru) 2021-11-29

Family

ID=72043773

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202192254A EA202192254A1 (ru) 2019-02-15 2020-02-14 Fcmr-связывающие молекулы и их применение

Country Status (13)

Country Link
US (1) US20220089725A1 (ru)
EP (1) EP3924388A4 (ru)
JP (1) JP2022520817A (ru)
KR (1) KR20210139273A (ru)
CN (1) CN113993895A (ru)
AU (1) AU2020222408A1 (ru)
CA (1) CA3130225A1 (ru)
EA (1) EA202192254A1 (ru)
IL (1) IL285585A (ru)
MX (1) MX2021009767A (ru)
SG (1) SG11202108837WA (ru)
TW (1) TW202035461A (ru)
WO (1) WO2020163962A1 (ru)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3626254A1 (en) * 2012-03-16 2020-03-25 University Health Network Soluble toso protein and its use in treating autoimmune disorders
US9493561B2 (en) * 2013-07-03 2016-11-15 University Health Network Antibodies to Toso
EP3098237B1 (en) * 2015-05-28 2018-08-01 Universität Zu Köln Anti-toso chimeric antigen receptor and its use

Also Published As

Publication number Publication date
JP2022520817A (ja) 2022-04-01
SG11202108837WA (en) 2021-09-29
CA3130225A1 (en) 2020-08-20
CN113993895A (zh) 2022-01-28
EP3924388A4 (en) 2023-02-15
EP3924388A1 (en) 2021-12-22
AU2020222408A1 (en) 2021-09-09
US20220089725A1 (en) 2022-03-24
IL285585A (en) 2021-09-30
TW202035461A (zh) 2020-10-01
MX2021009767A (es) 2021-11-17
WO2020163962A1 (en) 2020-08-20
KR20210139273A (ko) 2021-11-22

Similar Documents

Publication Publication Date Title
JOP20210154B1 (ar) مثبطات kif18a
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
MX2021007104A (es) Inhibidores de kif18a.
EA202092907A1 (ru) Мультиспецифические связывающие белки и их усовершенствования
EA201992350A1 (ru) Комбинированные лекарственные средства, нацеленные на pd-1, tim-3 и lag-3
EA202191380A1 (ru) Антитела к альфа-синуклеину и их применение
EA202091747A1 (ru) Составы антитела b7-h4
EA202092086A1 (ru) Ингибиторы аргиназы
CR20220207A (es) Compuestos terapéuticos y métodos de uso
EA202090401A1 (ru) Анти-tim-3 антитела и их применение
EA201892225A1 (ru) АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ
EA202290054A1 (ru) Полиспецифические антитела, содержащие только тяжелые цепи, которые связываются с cd22 и cd3
EA202190807A1 (ru) Антитела к синуклеину
EA202092125A1 (ru) Антитела против рецептора фолата 1 и их применения
EA202090014A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
EA202191478A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
EA202190588A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
EA202090372A1 (ru) Универсальные соединения авт и их применение
EA202191476A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
EA202191769A1 (ru) Тубулизины и конъюгаты белок-тубулизин
EA202090387A1 (ru) Белки, связывающие nkg2d, cd16 и flt3
EA202092518A1 (ru) Композиции и способы лечения рака
EA201790336A1 (ru) Антитела к ангиопоэтинподобному белку 4 и способы применения
EA202192488A1 (ru) Антитела против tsg-6 и их применения